Transaction DateRecipientSharesTypePriceValue
10th August 2020David Phillips797Bona fide gift$0.00
10th August 2020David Phillips797Bona fide gift$0.00
28th July 2020Anthony P Iii Bihl851Grant/award etc.$0.00
30th June 2020Bryan T Baldasare1,337Payment by withholding$23.29$31,138.73
30th June 2020Bryan T Baldasare1,500Exercise of derivative$19.71$29,565.00
7th April 2020Felicia Williams202Open or private sale$6.20$1,252.40
6th April 2020Felicia Williams671Exercise of derivative$0.00
23rd March 2020Felicia Williams422Open or private sale$4.92$2,075.23
23rd March 2020Felicia Williams1,040Exercise of derivative$0.00
16th March 2020Felicia Williams1,550Open or private purchase$6.02$9,331.00
Meridian Bioscience
Meridian Bioscience logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.


Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.


Ticker: VIVO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 794172
Employees: 660
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $63 M (0%)
Receivables, Net, Current: $42 M (19%)
Inventory, Net: $60 M (0%)
Assets, Current: $174 M (20%)
Property, Plant and Equipment, Net: $31 M (0%)
Other Assets, Noncurrent: $215 M (43%)
Assets: $420 M (0%)
Accounts Payable, Current: $13 M (86%)
Accrued Liabilities, Current: $5 M (29%)
Liabilities, Current: $44 M (107%)
Long-term Debt, Excluding Current Maturities: $99 M (30%)
Common Stock, Shares, Issued: $43 M (0%)
Additional Paid in Capital, Common Stock: $136 M (2%)
Retained Earnings (Accumulated Deficit): $103 M (62%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $5 M (2%)
Stockholders' Equity (Parent): $233 M (0%)
Liabilities and Equity: $420 M (28%)
Revenue: $85 M (-55%)
Cost of Revenue: $29 M (-59%)
Gross Margin: $56 M (-52%)
Research and Development: $7 M (-60%)
Sales and Marketing: $6 M (-67%)
General and Administrative Expenses: $12 M (-60%)
Restructuring Charges: $93 Th (0%)
Operating Income/Loss: $35 M (0%)
Other Income, net: $208 Th (-31%)
Provision for income taxes: $7 M (-37%)
EPS (basic): $0.64 (-31%)
EPS (diluted): $0.64 (-30%)